Trial · NCT02568644
Ginger Capsules for the Acute Treatment of Migraine Attacks
NCT02568644, Not applicable, Completed, Federal University of Minas Gerais; results first posted 2020-04-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ginger Capsules for the Acute Treatment of Migraine Attacks. Trials, record NCT02568644. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02568644
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ginger Capsules for the Acute Treatment of Migraine Attacks
- NCT number
- NCT02568644
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 60 participants, actual
- Lead sponsor
- Federal University of Minas Gerais
- Conditions
- Migraine
- Interventions
- Extract of ginger, Cellulose, Intravenous ketoprofen
- First posted
- 2015-10-06
- Last updated
- 2020-04-07
- Results first posted
- 2020-04-07
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Headache Severity. | 2 hours | The severity of headache was assessed with four-point scale. Scale ranges: 0 - Absence of pain, 1 - Mild Pain, 2 - Moderate Pain and 3 - Severe pain Higher scores mean a worse outcome |
| Primary | Change in Headache Severity. | 2 hours | The severity of headache was assessed with visual numeric scale. Scale ranges: from zero (absence of pain) to 10 (maximum intensity of pain). Higher scores mean a worse outcome. |
| Primary | Change in Headache Severity. | 2 hours | The severity of headache was assessed with faces pain scale. It is a self-reported pain scale consisting of face drawings which have a score ranging from zero (absence of pain) to five (maximal intensity of pain). Higher scores mean a worse outcome. |
| Secondary | Change in Serum Levels of Biomarkers. | 2 hours | Evaluated biomarkers: neurotrophic factors and inflammatory mediators. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Headache Severity. | 2 hours | units on a scale | MEAN | |
| PRIMARY | Change in Headache Severity. | 2 hours | units on a scale | MEAN | |
| PRIMARY | Change in Headache Severity. | 2 hours | units on a scale | MEAN | |
| SECONDARY | Change in Serum Levels of Biomarkers. | 2 hours | Brain derived neurotrophic factor - BDNF (pg/mL) | BDNF (pg/mL) | MEDIAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Headache Severity. | Extract of Ginger | 0.81 | Standard Deviation 0.04 | units on a scale | |
| Change in Headache Severity. | Cellulose | 0.97 | Standard Deviation 0.07 | units on a scale | |
| Change in Headache Severity. | Extract of Ginger | 1.03 | Standard Deviation 0.29 | units on a scale | |
| Change in Headache Severity. | Cellulose | 2.30 | Standard Deviation 0.46 | units on a scale | |
| Change in Headache Severity. | Extract of Ginger | 0.43 | Standard Deviation 0.13 | units on a scale | |
| Change in Headache Severity. | Cellulose | 0.90 | Standard Deviation 0.18 | units on a scale | |
| Change in Serum Levels of Biomarkers. | Extract of Ginger | 6077 | 95% Confidence Interval 5694 to 6944 | BDNF (pg/mL) | |
| Change in Serum Levels of Biomarkers. | Cellulose | 6503 | 95% Confidence Interval 5929 to 7244 | BDNF (pg/mL) |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Extract of Ginger | 30 | |
| Overall Study | STARTED | Cellulose | 30 | |
| Overall Study | COMPLETED | Extract of Ginger | 30 | |
| Overall Study | COMPLETED | Cellulose | 30 | |
| Overall Study | NOT COMPLETED | Extract of Ginger | 0 | |
| Overall Study | NOT COMPLETED | Cellulose | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dyspepsia | Gastrointestinal disorders | Extract of Ginger | 3 | 30 | |
| other | Dyspepsia | Gastrointestinal disorders | Cellulose | 0 | 30 | |
| other | Dizziness | Gastrointestinal disorders | Extract of Ginger | 0 | 30 | |
| other | Dizziness | Gastrointestinal disorders | Cellulose | 1 | 30 | |
| other | Nausea | Gastrointestinal disorders | Extract of Ginger | 0 | 30 | |
| other | Nausea | Gastrointestinal disorders | Cellulose | 2 | 30 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Extract of Ginger | ||
| Total, all-cause mortality | Cellulose | ||
| Total, other adverse events | Extract of Ginger | 3 | 30 |
| Total, other adverse events | Cellulose | 3 | 30 |
| Total, serious adverse events | Extract of Ginger | 0 | 30 |
| Total, serious adverse events | Cellulose | 0 | 30 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29768938 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Extract of Ginger vs Cellulose: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02568644
GET https://conductscience.org/api/trials/v1/NCT02568644/registered